BM
NBIX icon

Brandywine Managers’s Neurocrine Biosciences NBIX Stock Holding History

Brandywine Managers’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-2,700
Closed -$260K – 43
2020
Q3 		$260K Hold
2,700
– – 0.49% 35
2020
Q2 		$329K Hold
2,700
– – 1.35% 26
2020
Q1 		$234K Hold
2,700
– – 0.08% 29
2019
Q4 		$290K Hold
2,700
– – 0.09% 39
2019
Q3 		$243K Hold
2,700
– – 0.08% 38
2019
Q2 		$228K Hold
2,700
– – 0.09% 43
2019
Q1 		$238K Sell
2,700
-900
-25% -$75.2K 0.1% 46
2018
Q4 		$257K Buy
+3,600
New +$345K 0.12% 35

Other funds holding NBIX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Brandywine Managers's NBIX Position: Q4 2020 in Review

Brandywine Managers sold out of Neurocrine Biosciences (NBIX) in Q4 2020, closing a stake of 2,700 shares — an estimated $260K sold.

Brandywine Managers first reported a position in NBIX in Q4 2018 and held it in 8 quarters. The position peaked at $329K in Q2 2020. 405 funds tracked by Wall St. Rank hold NBIX as of Q4 2020.

  • Brandywine Managers reported no remaining Neurocrine Biosciences position as of Q4 2020 after selling out during the quarter.
  • Brandywine Managers sold 2,700 Neurocrine Biosciences shares in Q4 2020, an estimated $260K.
  • Brandywine Managers first reported a position in Neurocrine Biosciences in Q4 2018 and held it in 8 quarters.
  • Brandywine Managers's Neurocrine Biosciences position peaked at $329K in Q2 2020.
  • 405 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2020.

Based on Brandywine Managers's 13F filing for Q4 2020, filed 12 Feb 2021.